British Columbia Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.02M | Sell |
18,208
-5,012
| -22% | -$1.71M | 0.04% | 330 |
|
|
2025
Q4 | $9.23M | Buy |
23,220
+4,481
| +24% | +$1.98M | 0.05% | 282 |
|
|
2025
Q3 | $8.54M | Sell |
18,739
-1,732
| -8% | -$705K | 0.05% | 261 |
|
|
2025
Q2 | $6.68M | Sell |
20,471
-4,195
| -17% | -$1.16M | 0.04% | 310 |
|
|
2025
Q1 | $6.66M | Buy |
24,666
+84
| +0.3% | +$21.6K | 0.04% | 329 |
|
|
2024
Q4 | $5.78M | Buy |
24,582
+3,474
| +16% | +$914K | 0.03% | 381 |
|
|
2024
Q3 | $5.81M | Sell |
21,108
-3,109
| -13% | -$809K | 0.03% | 350 |
|
|
2024
Q2 | $5.88M | Buy |
24,217
+9,234
| +62% | +$1.46M | 0.04% | 348 |
|
|
2024
Q1 | $2.24M | Buy |
14,983
+599
| +4% | +$99.9K | 0.02% | 523 |
|
|
2023
Q4 | $2.75M | Buy |
14,384
+3,063
| +27% | +$522K | 0.02% | 440 |
|
|
2023
Q3 | $2M | Buy |
11,321
+144
| +1% | +$27.5K | 0.02% | 446 |
|
|
2023
Q2 | $2.12M | Buy |
11,177
+219
| +2% | +$43.4K | 0.02% | 458 |
|
|
2023
Q1 | $2.2M | Buy |
10,958
+324
| +3% | +$68.1K | 0.02% | 439 |
|
|
2022
Q4 | $2.53M | Sell |
10,634
-1,274
| -11% | -$272K | 0.03% | 393 |
|
|
2022
Q3 | $2.38M | Sell |
11,908
-2,017
| -14% | -$385K | 0.03% | 409 |
|
|
2022
Q2 | $2.03M | Sell |
13,925
-4,537
| -25% | -$644K | 0.02% | 502 |
|
|
2022
Q1 | $3.02M | Sell |
18,462
-2,486
| -12% | -$379K | 0.02% | 525 |
|
|
2021
Q4 | $3.55M | Sell |
20,948
-711
| -3% | -$132K | 0.02% | 533 |
|
|
2021
Q3 | $4.09M | Sell |
21,659
-3
| -0% | -$563 | 0.02% | 490 |
|
|
2021
Q2 | $3.67M | Buy |
21,662
+2,639
| +14% | +$387K | 0.02% | 536 |
|
|
2021
Q1 | $2.69M | Sell |
19,023
-508
| -3% | -$76.4K | 0.02% | 572 |
|
|
2020
Q4 | $2.54M | Sell |
19,531
-382
| -2% | -$51K | 0.02% | 576 |
|
|
2020
Q3 | $2.9M | Buy |
19,913
+1,872
| +10% | +$266K | 0.02% | 481 |
|
|
2020
Q2 | $2.67M | Buy |
18,041
+5,844
| +48% | +$788K | 0.03% | 462 |
|
|
2020
Q1 | $1.33M | Sell |
12,197
-14,007
| -53% | -$1.62M | 0.02% | 475 |
|
|
2019
Q4 | $3.02M | Buy |
26,204
+9,094
| +53% | +$907K | 0.02% | 544 |
|
|
2019
Q3 | $1.38M | Sell |
17,110
-5,259
| -24% | -$416K | 0.01% | 657 |
|
|
2019
Q2 | $1.62M | Buy |
22,369
+1,653
| +8% | +$127K | 0.01% | 707 |
|
|
2019
Q1 | $1.94M | Sell |
20,716
-2,104
| -9% | -$176K | 0.02% | 662 |
|
|
2018
Q4 | $1.66M | Buy |
22,820
+2,891
| +15% | +$222K | 0.01% | 674 |
|
|
2018
Q3 | $1.74M | Sell |
19,929
-7,096
| -26% | -$714K | 0.02% | 620 |
|
|
2018
Q2 | $2.66M | Sell |
27,025
-6,236
| -19% | -$619K | 0.02% | 595 |
|
|
2018
Q1 | $3.96M | Sell |
33,261
-1,244
| -4% | -$160K | 0.03% | 550 |
|
|
2017
Q4 | $4.38M | Buy |
+34,505
| New | +$4.34M | 0.03% | 526 |
|
|
2016
Q4 | – | Sell |
-9,678
| Closed | -$656K | – | 694 |
|
|
2016
Q3 | $656K | Sell |
9,678
-4,699
| -33% | -$332K | 0.01% | 665 |
|
|
2016
Q2 | $798K | Hold |
14,377
| – | – | 0.01% | 664 |
|
|
2016
Q1 | $902K | Sell |
14,377
-33,653
| -70% | -$2.24M | 0.01% | 652 |
|
|
2015
Q4 | $4.52M | Buy |
48,030
+26,023
| +118% | +$2.41M | 0.04% | 470 |
|
|
2015
Q3 | $1.77M | Buy |
22,007
+5,853
| +36% | +$650K | 0.02% | 561 |
|
|
2015
Q2 | $1.94M | Buy |
+16,154
| New | +$1.93M | 0.02% | 579 |
|
Other funds holding ALNY
VPM
VCM
British Columbia Investment Management's ALNY Position: Q1 2026 in Review
British Columbia Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q1 2026, selling an estimated $1.71M and leaving 18,208 shares worth $6.02M. The position accounts for 0.04% of the portfolio, ranked #330.
British Columbia Investment Management first reported a position in ALNY in Q2 2015 and has held it in 40 quarters since. The position peaked at $9.23M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- British Columbia Investment Management held 18,208 shares of Alnylam Pharmaceuticals worth $6.02M as of Q1 2026.
- British Columbia Investment Management sold 5,012 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.71M.
- Alnylam Pharmaceuticals made up 0.04% of British Columbia Investment Management's portfolio in Q1 2026, its #330 holding.
- British Columbia Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
- British Columbia Investment Management's Alnylam Pharmaceuticals position peaked at $9.23M in Q4 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on British Columbia Investment Management's 13F filing for Q1 2026, filed 14 May 2026.